Showing 591-600 of 7239 results for "".
Stirring the Pot: Cannabinoids and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/stirring-the-pot-cannabinoids-and-atopic-dermatitis/20565/Cannabinoids are a diverse group of compounds that may hold significant therapeutic capabilities applicable to many areas of medicine, including dermatology.Mineral Sunscreens with Iron Oxides are Underused for Dyschromia in Skin of Color
https://practicaldermatology.com/topics/skin-of-color/mineral-sunscreens-with-iron-oxides-are-underused-for-dyschromia-in-skin-of-color/23697/A local survey highlights the opportunity for dermatologists to counsel and educate skin of color patients on the use of tinted mineral sunscreens for bothersome dyschromia.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.Open Payments Program: Does it Enhance Open Discussion About Financial Ties Between Dermatologists and Industry?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/open-payments-program-does-it-enhance-open-discussion-about-financial-ties-between-dermatologists-and-industry/23619/The majority of physicians practicing in the United States have received some form of compensation from private industry during their careers. These payments may include consulting fees, compensation for speaking engagements, and stock options. Certain payments take indirect forms, such as physicUpdate on Atopic Dermatitis 2018
https://practicaldermatology.com/topics/general-topics/update-on-atopic-dermatitis-2018/20354/A look at the pathophysiology of AD, including structural and immunologic contributors, as well as new therapeutic developments with an eye toward breakthroughs on the horizon.Newly Approved Therapies for the Treatment of Plaque Psoriasis in Adults
https://practicaldermatology.com/topics/psoriasis/newly-approved-therapies-for-the-treatment-of-plaque-psoriasis-in-adults/23213/Here’s a closer a look at recently approved agents.Monitoring Biologic Therapy In Psoriasis: A Primer
https://practicaldermatology.com/topics/psoriasis/monitoring-biologic-therapy-in-psoriasis-a-primer/20931/Treatments are generally safe and well-tolerated, however, prescribers must monitor for risk factors.The Placebo and Nocebo Effects in Dermatology
https://practicaldermatology.com/columns/clinical-focus-1/the-placebo-and-nocebo-effects-in-dermatology/23559/Increasing evidence suggests that these effects—though not fully understood—may be harnessed for patient care.Cosmeceuticals Series, Part 2: Antioxidants
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-series-part-2-antioxidants/21395/The second article in this quarterly series examines how cosmeceuticals containing antioxidants can mitigate UV-induced damage.Finally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."